Steven Rubin Net Worth

The estimated Net Worth of Steven D Rubin is at least $10.8 million dollars as of 5 January 2024. Mr. Rubin owns over 10,000 units of Opko Health Inc stock worth over $9,652,862 and over the last 17 years he sold OPK stock worth over $0. In addition, he makes $1,131,200 as Executive Vice President - Administration et Director at Opko Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rubin OPK stock SEC Form 4 insiders trading

Steven has made over 29 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of OPK stock worth $8,700 on 5 January 2024.

The largest trade he's ever made was exercising 5,832,598 units of Opko Health Inc stock on 31 January 2015 worth over $3,207,929. On average, Steven trades about 85,755 units every 67 days since 2007. As of 5 January 2024 he still owns at least 6,187,732 units of Opko Health Inc stock.

You can see the complete history of Mr. Rubin stock trades at the bottom of the page.

Steven Rubin biography

Steven D. Rubin Esq., J.D. serves as Executive Vice President - Administration, Director of the Company. Mr. Rubin has served as Executive Vice President – Administration since May 2007 and as a director of the Company since February 2007. Mr. Rubin currently serves on the board of directors of Red Violet, Inc. (NASDAQ CM:RDVT), a software and services company, Non-Invasive Monitoring Systems, Inc. (OTC US:NIMU), a medical device company, Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a publicly traded biotechnology company developing new treatments for viral diseases, Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical stage biopharmaceutical company dedicated to treating patients suffering from rare and ultra-rare disease caused by premature termination codon nonsense mutations, Castle Brands, Inc. (NYSE American:ROX), a developer and marketer of premium brand spirits, Neovasc, Inc. (NASDAQ CM:NVCN), a company that develops and markets medical specialty vascular devices, and ChromaDex Corp. (NASDAQ CM:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age. Mr. Rubin previously served as a director of VBI Vaccines, Inc. (NASDAQ CM:VBIV), a biopharmaceutical company developing next generation vaccines, BioCardia, Inc.(OTC US:BCDA), clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, Cogint, Inc. (NASDAQ GM:COGT), now known as Fluent, Inc. (NASDAQ:FLNT), an information solutions provider focused on the data-fusion market, prior to the spin-off of its data and analytics operations and assets into Red Violet, Inc., Kidville, Inc. (OTCBB:KVIL), which operates large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds, Sevion Therapeutics, Inc., prior to its merger with Eloxx Pharmaceuticals, Inc., Dreams, Inc. (NYSE American:DRJ), a vertically integrated sports licensing and products company, SciVac Therapeu

What is the salary of Steven Rubin?

As the Executive Vice President - Administration et Director of Opko Health Inc, the total compensation of Steven Rubin at Opko Health Inc is $1,131,200. There are 2 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of $1,405,200.

How old is Steven Rubin?

Steven Rubin is 59, he's been the Executive Vice President - Administration et Director of Opko Health Inc since 2007. There are 17 older and 4 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.

What's Steven Rubin's mailing address?

Steven's mailing address filed with the SEC is OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI, FL, 33137.

Insiders trading at Opko Health Inc

Over the last 18 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... et Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.

What does Opko Health Inc do?

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig

Complete history of Mr. Rubin stock trades at Chromadex Corp, Opko Health Inc, VBI Vaccines, Cocrystal Pharma Inc, Red Violet Inc et Eloxx Pharmaceuticals Inc

Opko Health Inc executives and stock owners

Opko Health Inc executives and other stock owners filed with the SEC include:

• Phillip Frost,
  Chairman of the Board, Chief Executive Officer
• Jane Hsiao,
  Vice Chairman of the Board, Chief Technical Officer
• Steven Rubin,
  Executive Vice President - Administration, Director
• Adam E. Logal,
  Sr. VP & CFO
• Dr. Phillip Frost Ph.D.,
  Chairman & CEO
• Adam Logal,
  Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
• Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.,
  Vice Chairman & Chief Technical Officer
• Steven D. Rubin Esq., J.D.,
  Exec. VP of Admin. & Director
• Richard Pfenniger,
  Independent Director
• John Paganelli,
  Independent Director
• Richard Krasno,
  Independent Director
• Richard Lerner,
  Independent Director
• Robert Fishel,
  Independent Director
• Alice Yu,
  Independent Director
• Yvonne Briggs,
  Investor Relations
• Anthony Japour,
  Independent Director
• Geoff Monk,
  President of BioReference Laboratories
• Tony Cruz,
  Chief Executive Officer, Transition Therapeutics, Inc
• Charles Bishop,
  Chief Executive Officer of OPKO Renal
• Jon Cohen,
  Director, Executive Chairman of BioReference Laboratories
• Dr. David Okrongly Ph.D.,
  Pres of OPKO Diagnostics
• Jane Pine Wood Esq., J.D.,
  Chief Legal Officer of Bio-Reference Laboratories
• Dr. Akhtar Ashfaq,
  Sr. VP of Clinical R&D and Medical Affairs
• James DeMarco,
  Sr. VP of Pharmaceutical Sales
• Dr. Arie Gutman,
  Pres of API
• Alexis Borisy,
  Director
• Phillip Md Et Al Frost Gamm...,
  CEO & Chairman
• Gary J. Nabel,
  Chief Innovation Officer
• Phillip Md Et Al Frost Neva...,
  CEO & Chairman
• Phillip Md Et Al Frost,
  CEO & Chairman
• Roger Md Medel,
  
• Prem A Lachman,
  
• Gamma Investment Trust Frost,
  10% owner
• Subbarao V Uppaluri,
  Senior VP- CFO
• Thomas E Beier,
  Director
• Robert A Baron,
  Director
• Michael Reich,
  Director
• David A Eichler,
  Director
• Dmitry Kolosov,
  Director
• Md Pascal J Goldschmidt,,
  Director
• Elias A. Zerhouni,
  Vice Chairman and President